{"id":22475,"date":"2026-06-17T18:14:00","date_gmt":"2026-06-17T16:14:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=3218ff5562bc858110b1a79d3fdb5c64"},"modified":"2026-06-17T18:14:00","modified_gmt":"2026-06-17T16:14:00","slug":"quanthealth-expands-executive-team-with-world-class-medical-and-innovation-leaders","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=22475","title":{"rendered":"QuantHealth Expands Executive Team with World-Class Medical and Innovation Leaders"},"content":{"rendered":"

\nIndustry veterans from leading pharma and AI organizations will help build the predictive infrastructure that will power the future of clinical development<\/i><\/p>

TEL AVIV, Israel--(BUSINESS WIRE)--QuantHealth<\/a>, the leader in AI-powered clinical trial simulation, today announced the appointment of four executives from the world\u2019s top pharmaceutical and AI organizations to its executive team. The additions strengthen QuantHealth's leadership capabilities as predictive simulation emerges as a critical capability for pharmaceutical companies seeking to improve trial design, reduce development risks, and accelerate the delivery of new therapies to patients.<\/p><\/a><\/a>

\nJoining the company are Francisco Beca<\/a>, MD, PhD, as Chief Medical Officer; Sukant Mittal<\/a>, MS, PhD, as Senior Vice President of Corporate Development and Strategy; Flavio Dormont<\/a>, MBA, PhD, as Vice President of Scientific Strategy; and Agya Garg<\/a> as Vice President of Product.<\/p>

\nThe appointments strengthen four of QuantHealth\u2019s key strategic pillars for growth: clinical leadership, scientific innovation, corporate development, and product innovation. Collectively, the new executives bring experience from leading organizations including Merck, Sanofi, Seagen, Novartis, Hopper, Aura, and Loris.AI.<\/p>

\n\"For decades, the industry has made clinical trial design decisions with no ability to predict outcomes before a study begins. Simulation is quickly becoming a standard component of clinical development, enabling teams to evaluate decisions before patients are enrolled,\u201d said Orr Inbar, CEO and co-founder of QuantHealth. \"The caliber of leaders joining QuantHealth reflects growing recognition of our industry leadership, but also an increasing understanding that we will fundamentally transform how medicines are developed.\"<\/p>

\n\"The pace of scientific discovery has never been greater, yet clinical development remains one of the biggest bottlenecks in bringing new medicines to patients,\" said Francisco Beca, MD, PhD, Chief Medical Officer of QuantHealth. \"Predictive simulation gives development teams an entirely new way to evaluate trial decisions before a study begins. I believe this approach has the potential to fundamentally improve development success rates and accelerate patient access to innovative therapies.\"<\/p>

\nFrancisco Beca, MD, PhD, Chief Medical Officer\n<\/b>Beca brings deep experience across oncology, clinical development, and regulatory strategy, including leadership roles at Merck and Seagen, where he contributed to the BLA submission and FDA accelerated approval of market-leading oncology therapies. He has authored more than 35 peer-reviewed publications with over 6,500 citations.<\/p>

\nSukant Mittal, MS, PhD, Senior Vice President of Corporate Development and Strategy\n<\/b>Mittal brings more than 15 years of experience across life sciences\u2019 commercial strategy, investment diligence, operations, and growth initiatives. Throughout his career, he has supported the commercialization of multiple therapies, including a blockbuster therapy helping multiple sclerosis patients and a market-leading therapy for patients with atopic dermatitis.<\/p>

\nFlavio Dormont, MBA, PhD, Vice President of Scientific Strategy\n<\/b>Dormont brings more than a decade of experience applying advanced analytics and decision science to drug development. Most recently, he served as Global Director and Portfolio Head for Evidence Generation & Decision Science at Sanofi, where he helped establish the Sanofi\u2013QuantHealth partnership.<\/p>

\nAgya Garg, Vice President of Product\n<\/b>Garg brings more than 20 years of experience building and scaling technology and AI-driven products across healthcare and consumer industries. Most recently, she served as Head of Product at Loris.AI, leading the product organization through its acquisition by Contentsquare, and previously held leadership roles at Aura and Hopper.<\/p>

\n\"Francisco, Sukant, Flavio, and Agya bring deep experience with the industries we are working with. Together, they will help us build the predictive infrastructure that enables pharmaceutical companies to make better development decisions and bring therapies to patients faster,\u201d said Inbar.<\/p>

\nTo learn more about QuantHealth, visit www.quanthealth.ai<\/b><\/a>.<\/p>

\nAbout QuantHealth<\/b><\/p>

\nQuantHealth is the global leader for AI clinical trial simulation, bringing together the industry\u2019s most advanced clinical trial simulations portfolio \u2014 600+ trial simulations across 30 diseases with up to 90% prediction accuracy \u2014 and the category's largest real-world data set to help life sciences and biotechnology organizations improve the potential of clinical trial successes. QuantHealth solutions use real-world data and predictive modeling to simulate trials at scale, optimize protocols, reduce risk, and accelerate timelines. The company is a trusted partner for twelve of the top 20 global pharmaceutical companies.<\/p> Contacts<\/b>

\nMedia Contact<\/b>Mia Hinz\nSolComms\nquanthealth@solcomms.co<\/a><\/p>","protected":false},"excerpt":{"rendered":"

Industry veterans from leading pharma and AI organizations will help build the predictive infrastructure that will power the future of clinical developmentTEL AVIV, Israel–(BUSINESS WIRE)–QuantHealth, the leader in AI-powered clinical trial simulati…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-22475","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/22475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22475"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/22475\/revisions"}],"predecessor-version":[{"id":22476,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/22475\/revisions\/22476"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22475"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22475"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}